Supplementary Tables from Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy

Table S1: Targeted gene panel for DNA sequencing Table S2: List of genes in the custom Nanostring gene panel Table S3: Clinical characteristics of the patient cohort. Table S4: Predicted minimum tumor cellularity estimated by targeted DNA sequencing. Table S5: Somatic mutation calls from targeted DNA-sequencing. Table S6: Germline mutation calls from targeted DNA sequencing. Table S7: Comparison of non-silent mutations detected by targeted sequencing and whole exome sequencing (WES). Table S8: Differential gene expression between treated and untreated specimens Table S9: Gene expression values (normalized counts) of radical prostatectomy specimens Table S10: Gene expression values (normalized counts) of tumor biopsies Table S11: Gene expression values (normalized counts) of benign prostate specimens